Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma

by Beckey Trinh, Guacimara Ortega Sanchez, Petra Herzig, Heinz Läubli
Published 2019-02-01

Cytomegalovirus Enterocolitis in a Patient with Refractory Immune-Related Colitis

by Yoki Furuta, Hideaki Miyamoto, Hideaki Naoe, Miki Shimoda, Yukari Hinokuma, Tomohiro Miyamura, Azusa Miyashita, Satoshi Fukushima, Motohiko Tanaka, Yutaka Sasaki
Published 2020-02-01

Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma

by Yoko Maegawa, Taigo Kato, Shinichiro Fukuhara, Hiroshi Kiuchi, Ryoichi Imamura, Motohide Uemura, Norio Nonomura, Kazutoshi Fujita
Published 2020-09-01

Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab

by Fanny Zulay Acero Brand, Nicolas Suter, Jean-Philippe Adam, Bernard Faulques, Antonio Maietta, Denis Soulières, Normand Blais
Published 2018-03-01

Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors

by Carlos Eduardo de Andrea, Jose Luis Perez-Gracia, Eduardo Castanon, Mariano Ponz-Sarvise, Jose I. Echeveste, Ignacio Melero, Miguel F. Sanmamed, Maria Esperanza Rodriguez-Ruiz
Published 2020-01-01

Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?

by Heidar J. Albandar, Jacob Fuqua, Jasim M. Albandar, Salahuddin Safi, Samuel A. Merrill, Patrick C. Ma
Published 2021-02-01

Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy

by Terufumi Kubo, Yoshihiko Hirohashi, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Rena Morita, Toshihiko Torigoe
Published 2021-09-01

Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis

by Jamie S. Lin, Omar Mamlouk, Umut Selamet, Amanda Tchakarov, William F. Glass, Rahul A. Sheth, Rachel M. Layman, Ramona Dadu, Noha Abdel-Wahab, Maen Abdelrahim, Adi Diab, Cassian Yee, Ala Abudayyeh
Published 2021-01-01

Nivolumab-induced contact dermatitis in a patient with advanced lung cancer

by Shintaro Sato, Tomohiro Oba, Hiroki Ohta, Yuta Tsukahara, Gen Kida, Emiri Tsumiyama, Kenji Kusano, Tomotaka Nishizawa, Rie Kawabe, Hideaki Yamakawa, Keiichi Akasaka, Masako Amano, Hidekazu Matsushima
Published 2020-01-01

Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor

by Marta Rocha, João Correia de Sousa, Marta Salgado, António Araújo, Isabel Pedroto
Published 2018-12-01

Durvalumab‐induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non‐small cell lung cancer: A case report

by Maël Domblides, Margaux Geier, Chantal Decroisette, Renaud Descourt
Published 2021-04-01

Refractory dermatitis contributed by pityriasis versicolor: a case report

by Mingjia Li, Natalie Spaccarelli, Kari Kendra, Richard C. Wu, Claire Verschraegen
Published 2021-04-01

Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review

by Ammar Haikal, E Borba, Taqui Khaja, Gary Doolittle, Paul Schmidt
Published 2018-01-01

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer

by Xue Wang, Xiaomin Niu, Na An, Yile Sun, Zhiwei Chen
Published 2021-03-01

Severe immune thrombocytopenia induced by nivolumab in a patient with metastatic renal cell carcinoma

by Shinro Hata, Satoki Abe
Published 2020-09-01

Postherpes zoster programmed death-1 inhibitor−associated zosteriform granulomatous reactions

by Simran A. Chadha, BS, Lida Zheng, MD, Joel C. Sunshine, MD, PhD, Lauren M. Guggina, MD, Cuong V. Nguyen, MD
Published 2020-12-01

Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report

by Jindřich Kopecký, Ondřej Kubeček, Tomáš Geryk, Birgita Slováčková, Petr Hoffmann, Miroslav Žiaran, Peter Priester
Published 2018-09-01

The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events

by Toshiya Fujisaki, Satoshi Watanabe, Takeshi Ota, Kohei Kushiro, Yusuke Sato, Miho Takahashi, Aya Ohtsubo, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Satoshi Hokari, Rie Kondo, Takao Miyabayashi, Tetsuya Abe, Satoru Miura, Hiroshi Tanaka, Masaaki Okajima, Masaki Terada, Naoya Matsumoto, Takashi Ishida, Akira Iwashima, Kazuhiro Sato, Hirohisa Yoshizawa, Nobumasa Aoki, Masachika Hayashi, Yasuyoshi Ohshima, Toshiyuki Koya, Toshiaki Kikuchi
Published 2021-09-01

Checkpoint inhibitor induced esophagitis with documented resolution on infliximab

by Frank W. Chen, Anne F. Liu, Amitabh Srivastava, Elizabeth Buchbinder, Shilpa Grover
Published 2020-12-01